Cargando…
Zebrafish Models for Dyslipidemia and Atherosclerosis Research
Atherosclerotic cardiovascular disease is the leading cause of death. Elevated circulating concentrations of lipids are a central pathogenetic driver of atherosclerosis. While numerous effective therapies for this condition have been developed, there is substantial unmet need for this pandemic illne...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159437/ https://www.ncbi.nlm.nih.gov/pubmed/28018294 http://dx.doi.org/10.3389/fendo.2016.00159 |
_version_ | 1782481770094002176 |
---|---|
author | Schlegel, Amnon |
author_facet | Schlegel, Amnon |
author_sort | Schlegel, Amnon |
collection | PubMed |
description | Atherosclerotic cardiovascular disease is the leading cause of death. Elevated circulating concentrations of lipids are a central pathogenetic driver of atherosclerosis. While numerous effective therapies for this condition have been developed, there is substantial unmet need for this pandemic illness. Here, I will review nutritional, physiological, genetic, and pathological discoveries in the emerging zebrafish model for studying dyslipidemia and atherosclerosis. The technical and physiological advantages and the pharmacological potential of this organism for discovery and validation of dyslipidemia and atherosclerosis targets are stressed through summary of recent findings. An emerging literature shows that zebrafish, through retention of a cetp ortholog gene and high sensitivity to ingestion of excess cholesterol, rapidly develops hypercholesterolemia, with a pattern of distribution of lipid species in lipoprotein particles similar to humans. Furthermore, recent studies leveraging the optical transparency of zebrafish larvae to monitor the fate of these ingested lipids have provided exciting insights to the development of dyslipidemia and atherosclerosis. Future directions for investigation are considered, with particular attention to the potential for in vivo cell biological study of atherosclerotic plaques. |
format | Online Article Text |
id | pubmed-5159437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51594372016-12-23 Zebrafish Models for Dyslipidemia and Atherosclerosis Research Schlegel, Amnon Front Endocrinol (Lausanne) Endocrinology Atherosclerotic cardiovascular disease is the leading cause of death. Elevated circulating concentrations of lipids are a central pathogenetic driver of atherosclerosis. While numerous effective therapies for this condition have been developed, there is substantial unmet need for this pandemic illness. Here, I will review nutritional, physiological, genetic, and pathological discoveries in the emerging zebrafish model for studying dyslipidemia and atherosclerosis. The technical and physiological advantages and the pharmacological potential of this organism for discovery and validation of dyslipidemia and atherosclerosis targets are stressed through summary of recent findings. An emerging literature shows that zebrafish, through retention of a cetp ortholog gene and high sensitivity to ingestion of excess cholesterol, rapidly develops hypercholesterolemia, with a pattern of distribution of lipid species in lipoprotein particles similar to humans. Furthermore, recent studies leveraging the optical transparency of zebrafish larvae to monitor the fate of these ingested lipids have provided exciting insights to the development of dyslipidemia and atherosclerosis. Future directions for investigation are considered, with particular attention to the potential for in vivo cell biological study of atherosclerotic plaques. Frontiers Media S.A. 2016-12-16 /pmc/articles/PMC5159437/ /pubmed/28018294 http://dx.doi.org/10.3389/fendo.2016.00159 Text en Copyright © 2016 Schlegel. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Schlegel, Amnon Zebrafish Models for Dyslipidemia and Atherosclerosis Research |
title | Zebrafish Models for Dyslipidemia and Atherosclerosis Research |
title_full | Zebrafish Models for Dyslipidemia and Atherosclerosis Research |
title_fullStr | Zebrafish Models for Dyslipidemia and Atherosclerosis Research |
title_full_unstemmed | Zebrafish Models for Dyslipidemia and Atherosclerosis Research |
title_short | Zebrafish Models for Dyslipidemia and Atherosclerosis Research |
title_sort | zebrafish models for dyslipidemia and atherosclerosis research |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159437/ https://www.ncbi.nlm.nih.gov/pubmed/28018294 http://dx.doi.org/10.3389/fendo.2016.00159 |
work_keys_str_mv | AT schlegelamnon zebrafishmodelsfordyslipidemiaandatherosclerosisresearch |